证券日报网讯1月6日，易瑞生物（300942）在互动平台回答投资者提问时表示，公司目前暂无脑机接口 相关领域的业务布局。 ...

格隆汇1月6日丨易瑞生物(300942.SZ)在投资者互动平台表示，公司目前暂无脑机接口相关领域的业务 布局。 ...

每经AI快讯，有投资者在投资者互动平台提问：请问贵公司是否有布局脑机接口相关领域的业务？ 易瑞生物（300942.SZ）1月6日在投资者互动平台表示，公司目前暂无脑机接口相关领域的业务布局。 （记者 王晓波） ...

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2026-001 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于 2025 年第四季度可转债转股情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300942 证券简称：易瑞生物 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，深圳市易瑞生物技术 股份有限公司（以下简称"公司"）现将 2025 年第四季度可转换公司债券（以 下简称"可转债"）转股及公司总股本变化情况公告如下： 一、可转债基本情况 （一）可转债发行情况 经中国证券监督管理委员会《关于同意深圳市易瑞生物技术股份有限公司向 不特定对象发行可转换公司债券注册的批复》（证监许可〔2023〕1447 号）同 意注册，公司于 2023 年 8 月 18 日向不特定对象发行可转换公司债券 3,281,967 张，每张面值为人民币 100.00 ...

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-076 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于控股股东及其一致行动人权益变动 触及 1%整数倍的提示性公告 公司控股股东及其一致行动人保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 一、本次权益变动情况 深圳市易瑞生物技术股份有限公司（以下简称"公司"或"本公司"）于 2025 年 10 月 13 日披露了《关于控股股东及其一致行动人减持股份的预披露公 告》（公告编号：2025-069），控股股东易瑞（海南）创业投资有限公司（以下 简称"易瑞创投"）及其一致行动人深圳易达瑞管理咨询合伙企业（有限合伙） （以下简称"易达瑞"）和深圳易凯瑞管理咨询合伙企业（有限合伙）（以下简 称"易凯瑞"）计划于上述公告披露之日起 15 个交易日后的 3 个月内以集中竞 价或大宗交易方式减持公司股份，具体情况如下： 1、持有公司股份 132,369,9 ...

Group 1 - The core point of the news is that Erye Biological conducted a block trade of 400,000 shares on December 3, with a transaction amount of 3.52 million yuan, accounting for 8.94% of the total transaction volume for the day [1][2] - The transaction price was 8.80 yuan, which represents a discount of 12.7% compared to the market closing price of 10.08 yuan [1][2]

Group 1 - On December 2, 2025, Erye Biological conducted a block trade of 550,000 shares, with a transaction amount of 4.8675 million yuan, accounting for 10.05% of the total transaction volume for the day [1][2] - The transaction price was 8.85 yuan per share, representing a discount of 13.15% compared to the market closing price of 10.19 yuan [1][2]

Group 1 - The company, EasyRegen Biotech (300942), responded to investor inquiries on its interactive platform regarding shareholder information disclosure [1] - The company stated that the number of shareholders will be disclosed in its periodic reports as per relevant regulatory requirements [1] - Investors are advised to pay attention to the company's subsequent announcements for further details [1]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-11-27 | 300942 | 易瑞生物 | 8.80 | 23.00 | | 202.40 国投证券股份有限 | 东兴证券股份有限 | | | | | | | | 公司汕头长平路证 | 公司上海陆家嘴证 | | | | | | | | 券营业部 | 券营业部 | 11月27日，易瑞生物大宗交易成交23万股，成交额202.4万元，占当日总成交额的6.13%，成交价8.8 元，较市场收盘价10.12元折价13.04%。 ...

Group 1: International Expansion - The company has established a marketing network covering over 60 countries and regions, enhancing its international presence through participation in industry exhibitions and targeted channel development [3] - The company is actively pursuing international certifications for multiple products to boost global brand recognition [4] - The partnership with Coherent is expected to accelerate market penetration and brand internationalization in the dairy sector [8] Group 2: Financial Performance - In Q3 2025, the company achieved a revenue of 186 million yuan, a year-on-year increase of 17.45% [4] - The net profit attributable to shareholders reached 18.02 million yuan, a significant increase of 362.49% year-on-year [4] - Non-recurring gains and losses impacted net profit by approximately 14.29 million yuan, primarily from asset disposals and government subsidies [4] Group 3: Pet Business Development - The company plans to expand its pet business into areas such as elderly disease prevention and pet consumption, building a diversified business ecosystem [5] - The pet diagnostics segment is projected to exceed 13 million yuan in revenue in 2024, indicating strong growth potential [6] Group 4: Strategic Partnerships - The agreement with Coherent, effective from June 16, 2025, sets a sales target of 73.06 million euros (approximately 600.83 million yuan) for the period from 2025 to 2029 [6] - The collaboration is expected to leverage Coherent's extensive customer base and sales network, enhancing the company's market reach [8] Group 5: Product Offerings and Market Solutions - The company provides comprehensive food safety testing solutions across the supply chain, ensuring high-quality standards in various food sectors [8] - The rapid testing technology is applicable to the prepared food industry, offering solutions for detecting mycotoxins, pesticide residues, and other contaminants [8]